Literature DB >> 3216474

[The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus].

Y Matsuhashi1, H Yamamoto.   

Abstract

We investigated enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus (MRSA) by elucidation of the structures of the enzymatic reaction products. According to the MIC data, MRSA, (46 strains) can be classified into 3 groups as follows. 1. Group I (35 strains) was highly resistant to gentamicin (GM) and tobramycin (TOB), and produced 2"-aminoglycosides phosphotransferase (APH (2"]. 2. Group II (8 strains) was sensitive to GM, but was highly resistant to TOB, and produced 4'-aminoglycosides adenylyl-transferase (AAD (4']. 3. Group III (3 strains) was sensitive to GM and TOB, but was highly resistant to kanamycin, and produced 3'-aminoglycosides phosphotransferase (APH (3']-III. Arbekacin (HBK) was the most stable antibiotic to all of the inactivating-enzymes produced by MRSA, and all MRSA were sensitive to HBK.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3216474

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  5 in total

1.  Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Reiko Sato; Yusuke Tanigawara; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

2.  Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Yusuke Tanigawara; Reiko Sato; Kunihiko Morita; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 3.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 4.  Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Authors:  Tetsuya Matsumoto
Journal:  Clin Pharmacol       Date:  2014-09-26

Review 5.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.